Please assess the completion status of the following clinical trial:

Trial Title: A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* BMI 18.0-35.0 kg/m2~* 45-120 kg, inclusive~* At screening, females must be non-pregnant and non-lactating, or of nonchildbearing potential (either surgically sterilized or physiologically incapable of becoming pregnant, or at least 1-year postmenopausal (amenorrhoea duration of 12 consecutive months); nonpregnancy will be confirmed for all females by a pregnancy test conducted at screening, (each) admission, and at follow-up.~* Female participants of child-bearing potential must agree to use adequate contraception from screening until 90 days after the follow-up visit.~* In good physical health on the basis of no clinically significant findings from medical history, physical examination (PE), laboratory tests, 12 lead ECG, and vital signs, as judged by the Investigator.~* Willingness and able to comply with the study protocol, in the investigator's judgement.~Exclusion Criteria:~* Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins.~* Positive drug or alcohol at screening and prior to first dose~* History of alcohol abuse or substance abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- AL001 (Type: EXPERIMENTAL): Up to six single ascending doses of AL001
- Saline Solution (Type: PLACEBO_COMPARATOR): Saline solution will be administered as a single infusion for each cohort in a ratio of 6 active and 2 placebo subjects

Based on this trial design, predict the completion outcome and termination type (if applicable).